The estimated Net Worth of Brian K Beeler is at least $24.9 Million dollars as of 17 September 2021. Mr. Beeler owns over 28,143 units of Horizon Therapeutics Plc stock worth over $7,300,733 and over the last 10 years he sold HZNP stock worth over $17,613,074. In addition, he makes $0 as Executive Vice President and General Counsel at Horizon Therapeutics Plc.
Brian has made over 17 trades of the Horizon Therapeutics Plc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 28,143 units of HZNP stock worth $3,036,911 on 17 September 2021.
The largest trade he's ever made was selling 74,898 units of Horizon Therapeutics Plc stock on 16 August 2021 worth over $7,939,188. On average, Brian trades about 12,543 units every 38 days since 2015. As of 17 September 2021 he still owns at least 62,775 units of Horizon Therapeutics Plc stock.
You can see the complete history of Mr. Beeler stock trades at the bottom of the page.
Brian K. Beeler is Executive Vice President, General Counsel of the Company. Mr. Beeler previously served as our senior vice president, legal and chief compliance officer from January 2015 until May 2015 and as our associate general counsel and chief compliance officer from January 2013 until January 2015. Prior to joining Horizon, Mr. Beeler served as associate general counsel for Fenwal, Inc., a global blood technology company, from December 2008 until December 2012. Before that, Mr. Beeler was senior counsel, business development, commercial and research and development at TAP Pharmaceuticals and Takeda Pharmaceuticals North America and also previously served as chief compliance officer at Schwartz Pharma.
Brian Beeler is 47, he's been the Executive Vice President and General Counsel of Horizon Therapeutics Plc since 2015. There are 19 older and 5 younger executives at Horizon Therapeutics Plc. The oldest executive at Horizon Therapeutics Plc is William Daniel, 67, who is the Independent Director.
Brian's mailing address filed with the SEC is C/O HORIZON THERAPEUTICS PLC, CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD, DUBLIN, L2, 4.
Over the last 13 years, insiders at Horizon Therapeutics Plc have traded over $454,905,275 worth of Horizon Therapeutics Plc stock and bought 11,809,010 units worth $58,823,653 . The most active insiders traders include Jeff Himawan, Woodlands Health Ventures F..., and Jean Francois Formela. On average, Horizon Therapeutics Plc executives and independent directors trade stock every 13 days with the average trade being worth of $12,248,018. The most recent stock trade was executed by Gino Santini on 2 October 2023, trading 23,092 units of HZNP stock currently worth $351,691.
at horizon therapeutics, we believe science and compassion must work together to transform lives. we are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. for us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.
Horizon Therapeutics Plc executives and other stock owners filed with the SEC include: